Blaire Anderson

Dr. Blaire Anderson


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
JHJoshua Hefler
Joshua Hefler
DLDayne Leon-Izquierdo
Dayne Leon-Izquierdo
Braulio Marfil-GarzaBraulio Marfil-Garza
Braulio Marfil-Garza
GMGlenda Meeberg
Glenda Meeberg
KVKevin Verhoeff
Kevin Verhoeff
ASAndrew Mark James Shapiro
Andrew Mark James Shapiro
Normothermic machine perfusion (NMP) has emerged as a valuable tool in the preservation of liver allografts before transplantation. Randomized trials have shown that replacing static cold storage (SCS) with NMP reduces allograft injury and improves graft utilization. The University of Alberta's liver transplant program was one of the early adopters of NMP in North America. Herein, we describe our seven-year experience applying NMP to extend preservation time in liver transplantation using a 'back-to-base' approach. From 2015 to 2021, 79 livers were transplanted following NMP compared to 386 after SCS only. NMP livers were preserved for a median time of 847min compared to 288.5min in the SCS cohort (p<0.0001). Despite this, we observed significantly improved 30-day graft survival (p=0.030), though no differences in long term patient survival, major complications or biliary or vascular complications. We also found that while SCS time was strongly associated with increased graft failure at one year in the SCS cohort (p=0.006), there was no such association amongst NMP livers (p=0.171). Our experience suggests that NMP can safely extend the total preservation time of liver allografts without increasing complications.

1 June 2021 in HPB
Verified
Journal Article
Closed access
NSNathalie Sela
Nathalie Sela
BABlaire Anderson
Blaire Anderson
AGAustin T. Granatowicz
Austin T. Granatowicz
EJEmily Jezewski
Emily Jezewski
AHArika L. Hoffman
Arika L. Hoffman

2 December 2024 in Annals of Hepato-Biliary-Pancreatic Surgery
Verified
Journal Article
Open access
PDF file
ZCZofia Czarnecka
Zofia Czarnecka
KVKevin Verhoeff
Kevin Verhoeff
DBDavid Bigam
David Bigam
KDKhaled Dajani
Khaled Dajani
ASAndrew Mark James Shapiro
Andrew Mark James Shapiro
BABlaire Anderson
Blaire Anderson
Zofia Czarnecka, Kevin Verhoeff, David Bigam, Khaled Dajani, James Shapiro, Blaire Anderson. Ann Hepatobiliary Pancreat Surg -0001;0:. https://doi.org/10.14701/ahbps.24-172

7 October 2020 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
BABlaire Anderson
Blaire Anderson
EJEmily Jezewski
Emily Jezewski
NSNathalie Sela
Nathalie Sela
SWScott Westphal
Scott Westphal
AHArika Hoffman
Arika Hoffman

19 January 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
Gavin LowGavin Low
Gavin Low
XQXu Jing Qian
Xu Jing Qian
ARAli Ramji
Ali Ramji
BABlaire Anderson
Blaire Anderson
SGSafwat Girgis
Safwat Girgis
MWMitchell Wilson
Mitchell Wilson
Combined hepatocellular cholangiocarcinoma (cHCC-CC) is a rare and poorly understood primary liver cancer. First identified over a century ago, it has been referred to by various names and reclassified multiple times since the initial description. Diagnosis is extremely challenging as the tumor can mimic hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC) on imaging or show overlapping features of both. The tumor may also be incorrectly diagnosed with biopsy due to inadequate tissue sampling. As such, many tumors are only correctly diagnosed histologically following surgical resection or transplantation for presumptive HCC. A variety of treatment options are available, although no national or international consensus exists regarding the optimal treatment strategy. Treatment outcomes vary with cHCC-CC showing an intermediate prognosis between HCC and ICC. In this updated review, we provide a conceptual overview of this intriguing neoplasm, including its classification and origins, epidemiology, clinical characteristics, and diagnostic and treatment options. Finally, we discuss the use of radiomics artificial intelligence (AI) to address challenges in lesion differentiation from HCC and ICC, and in predicting post-treatment survival and recurrence.

7 October 2024 in Livers
Verified
Journal Article
Open access
PDF file
DMDunavan Morris-Janzen
Dunavan Morris-Janzen
SJSukhdeep Jatana
Sukhdeep Jatana
KVKevin Verhoeff
Kevin Verhoeff
ASAndrew Mark James Shapiro
Andrew Mark James Shapiro
DBDavid Bigam
David Bigam
BABlaire Anderson
Blaire Anderson
Background/Objectives: Efforts to preoperatively risk stratify and optimize patients before liver resection allow for improvements in postoperative outcomes, with hypoalbuminemia being increasingly researched as a surrogate for nutrition, overall health and functional status. Given the paucity of studies examining the relationship between hypoalbuminemia and liver resection, this study aims to determine the impact of hypoalbuminemia on outcomes following liver resections using a large multicenter database. Methods: The American College of Surgeons–National Surgical Quality Improvement Program (2017–2021) database was used to extract the data of patients who underwent a hepatic resection. Two cohorts were defined; those with hypoalbuminemia (HA; <3.0 g/L) and those with normal albumin levels (≥3.0 g/L). Both baseline characteristics and 30-day postoperative complication rates were compared between the two cohorts. Multivariable logistic regression models were used to assess the independent effect of HA on various outcomes. Area under curve–receiver operating characteristic (AUC-ROC) curves were used to identify optimal albumin thresholds for both serious complications and mortality. Results: We evaluated 26,394 patients who underwent liver resections, with 1347 (5.1%) having preoperative HA. The HA patients were older (62.3 vs. 59.8; p < 0.001) and more likely to be of an ASA class ≥ 4 (13.0% vs. 6.5%; p < 0.001). The patients with HA had significantly more complications such as an increased length of stay, readmission, reoperation, sepsis, surgical site infection, bile leak, and need for transfusion. After controlling for demographics and comorbidities, HA remained a significant independent predictor associated with both 30-day serious complication rates (aOR 2.93 [CI 95% 2.36–3.65, p < 0.001]) and mortality (aOR 2.15 [CI 95% 1.38–3.36, p = 0.001]). The optimal cut-off for albumin with respect to predicting serious complications was 4.0 g/dL (sensitivity 59.1%, specificity 56.8%, AUC-ROC 0.61) and 3.8 g/dL (sensitivity 56.6%, specificity 68.3%, AUC-ROC 0.67) for mortality. Conclusions: In this large, retrospective database analysis, preoperative HA was significantly associated with 30-day morbidity and mortality rates following hepatic resection. Preoperative albumin may serve as a useful marker for risk stratification in conjunction with pre-existing calculators. Future studies evaluating the risk mitigation impact of nutrition and exercise prehabilitation in these patients and its capacity to modify hypoalbuminemia would be beneficial.